Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711516 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance
A Phase 4 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00711516 is a Phase 4 study that has completed, run by Cephalon. The registered enrollment target is 40 participants.
The verdict
NCT00711516, a Phase 4 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether treatment with armodafinil will provide improvements in prefrontal cortical activation in patients with OSAHS (Obstructive Sleep Apnea/Hypopnea Syndrome) who have residual sleepiness despite receiving nCPAP therapy.
Interventions
- DRUG Placebo
- DRUG Armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711516
The ClinicalTrials.gov registry entry for NCT00711516 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00711516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00711516 about?
NCT00711516 is a clinical study titled "Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance". The primary objective of this study is to determine whether treatment with armodafinil will provide improvements in prefrontal cortical activation in patients with OSAHS (Obstructive Sleep Apnea/Hypopnea Syndrome) who have residual sleepiness despite receiving nCPAP therapy.
What is the current status of trial NCT00711516?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00711516?
The interventions under investigation include: Placebo (DRUG), Armodafinil (DRUG).
Who is sponsoring clinical trial NCT00711516?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.